Perfil antipsicótico do canabidiol

Pedrazzi, João Francisco Cordeiro; Pereira, Ana Carolina de Castro Issy; Gomes, Felipe Villela; Del Bel, Elaine.
Medicina (Ribeiräo Preto) ; 47(2): 112-119, abr.-jun. 2014.
Artículo en Portugués | LILACS | ID: lil-753432

Documentos relacionados

  1. Behavioral effects induced by the cannabidiol analogs HU-502 and HU-556.
  2. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia.
  3. Cannabinoids, reward processing, and psychosis.
  4. Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses.
  5. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
  6. Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol.
  7. Cannabidiol (CBD) as a novel treatment in the early phases of psychosis.
  8. Perspectives toward cannabidiol (CBD) among youth in Early Psychosis Intervention programs: A qualitative study.
  9. [Progress in cannabis research from a pharmaceutical chemist's point of view].
  10. Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis.